Like every pharmaceutical company, GSK has seen patents expire on a string of blockbuster drugs, allowing generic rivals to ...

Climate Asset Management has raised more than $1 billion to invest in natural capital projects such as regenerative agriculture, its chief executive told Reuters.

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

Getting more effective drugs for patients in need as quickly as possible should be the ultimate reward and objective.

In a report released today, Peter Welford from Jefferies maintained a Buy rating on GlaxoSmithKline (GSK – Research Report), with a price ...

British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...

GSK has turned to Brooke Shields to get the message out about shingles vaccination. | GSK has turned to Brooke Shields to get ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...

Results presented at ESMO showed tumor response rates that matched the bar set by analysts for success. But they may not yet be enough to dispel doubts around TIGIT as a target.

A targeted immunotherapy being developed by iTeos Therapeutics and GSK, it was reported at #ESMO, delivered promising ...